TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04630743

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive and Behavioral intervention for the Management of Episodic Breathlessness
Description: The cognitive and behavioral brief intervention comprises two parts: In a first module, the intervention and the study team is introduced, the definition of episodic breathlessness is given and the individual characteristics of breathlessness episodes are recorded. Goals of the intervention are discussed. In a subsequent module on patient education and the strategies, the patient and intervention executor discuss the patients' assumptions about episodic breathlessness including triggers and already used management strategies for breathlessness episodes. This follows the presentation of the non-pharmacological strategies: movement of air/ handheld fan, forward lean, diaphragmatic breathing, distraction, pursed lips breathing, long breaths out and relaxation training. The patient selects 2-3 strategies and trains them with the intervention executor.
Study: NCT04825665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous force
Description: A buccally directed continuous tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar, bypassing the second premolar and attaching to the upper first premolar. The buccal tipping force will be checked and reactivated to the original level on the 28th day of the 8 week study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent force
Description: A buccally directed tipping force of 150 g is applied to the maxillary first premolar by a cantilever spring made of 0.017 x 0.025 beta-titanium-molybdenum alloy inserted in the tube of the upper first molar and attaching to the upper first premolar. The buccal tipping force will be removed every 21 days for a 7-day rest period, where a passive wire of the same gauge and material of the cantilever spring (0.017 x 0.025 beta-titanium-molybdenum alloy) will be placed instead to maintain the position of the upper first premolar during the rest period.
Study: NCT01622556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 35 mg/m2 IV/day x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: .8 mg/kg IV Q6h x 8 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 1.5 mg/kg/day x 3 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 150 cGy for 2 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
Study: NCT03893578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral valve-in-valve
Description: The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
Study: NCT02276417

Intervention type: OTHER
Intervention: Blood collection
Description: Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.

Intervention type: OTHER
Intervention: Urine collection
Description: Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.

Intervention type: OTHER
Intervention: Bioimpedance Analysis
Description: The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.

Intervention type: OTHER
Intervention: Cognitive Function Tests
Description: Cognitive function tests will be administered at 3, 6 and 12 months.

Intervention type: OTHER
Intervention: Quality-of-life Questionnaires
Description: Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.

Intervention type: OTHER
Intervention: Physical Function Tests
Description: Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.

Intervention type: OTHER
Intervention: Blood Collection
Description: The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
Study: NCT04722562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat (BAY1021189)
Description: Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
Study: NCT02321852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
Study: NCT03775486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Olaparib
Description: Matching tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel+carboplatin
Description: Standard of Care chemotherapy (squamous and non-squamous patients)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel+carboplatin
Description: Standard of Care chemotherapy (squamous and non-squamous patients)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+carboplatin
Description: Standard of Care chemotherapy (squamous patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+carboplatin
Description: Standard of Care chemotherapy (squamous patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+carboplatin
Description: Standard of Care chemotherapy (non-squamous patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+carboplatin
Description: Standard of Care chemotherapy (non-squamous patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+cisplatin
Description: Standard of Care chemotherapy (squamous patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+cisplatin
Description: Standard of Care chemotherapy (squamous patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+cisplatin
Description: Standard of Care chemotherapy (non-squamous patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed+cisplatin
Description: Standard of Care chemotherapy (non-squamous patients only)
Study: NCT02846272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation of MRI changes in subjects
Study: NCT00784940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg, orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg, orally, once daily
Study: NCT02271438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive a single oral dose of 12 capsules (12\*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6\*140 mg capsules) of ibrutinib in Treatment B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib-matching placebo
Description: Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib-matching placebo
Description: Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching placebo
Description: Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching placebo
Description: Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin-matching placebo
Description: Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
Study: NCT00631839

Intervention type: RADIATION
Intervention: Thoracic 3-D Conformal Radiotherapy
Description: Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies \>=6MV.
Study: NCT04002843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paraclinical evaluation of single fibre
Description: ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paraclinical evaluation of single fibre
Description: ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.

Intervention type: OTHER
Group type: OTHER
Intervention: paraclinical evaluation of single fibre
Description: ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into one elbow flexor muscle (biceps brachialis, anterior brachialis) on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.
Study: NCT04508582

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular magnetic resonance
Description: Imaging of the heart with CMR, without use of contrast agents.
Study: NCT02321852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triflusal
Description: Once daily oral administration of 600 mg triflusal Disgren® for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral administration of placebo mannitol for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily oral administration of placebo mannitol for 7 days
Study: NCT03802552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Description: oral one-time dose of cefadroxil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil
Description: oral one-time dose of cefadroxil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: oral one-time dose of cephalexin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: oral one-time dose of cephalexin
Study: NCT00945646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FST-201 (dexamethasone 0.1%) Otic Suspension
Description: Instill four drops times two times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Instill four times two times a day
Study: NCT02914834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standardized acupuncture treatment administered for 30 minutes each session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-pain related video health education
Description: Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
Study: NCT01213381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iniparib (SAR240550 - BSI-201)
Description: Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous
Study: NCT04847024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: 40 mg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: 50 mg IV
Study: NCT03794895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler
Description: Doing doppler for women having IUCD associated menorrhagia
Study: NCT03330509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK intervention
Description: An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK intervention
Description: An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK intervention
Description: An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPARK intervention
Description: An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
Study: NCT02479841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self management program
Study: NCT03530891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided lag screw fixation
Description: Under general anaesthesia: Patient specific pre operative prefabricated surgical guide will be used intra operative for open reduction and internal fixation for anterior mandibular fracture using lag screws.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lag screw fixation
Description: Under general anaesthesia: Open reduction and internal fixation for anterior mandibular fracture utilising lag screws.
Study: NCT03353376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group care with Empowerment model
Description: Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: group care with Empowerment model
Description: Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
Study: NCT02541344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dose 1 of IQP-VV-102
Description: Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dose 2 of IQP-VV-102
Description: Dose 2 (D2) group will take 4 tablets with active ingredients.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102.
Study: NCT00746369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA HIV Prevention Intervention
Description: Three individual sessions- behavioral intervention for incarcerated female adolescents.
Study: NCT02704767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tarceva

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03398096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy
Description: Ultrasound guided cardiac shock wave therapy (CSWT) is a new treatment method offering an alternative to revascularization by stimulating angiogenesis. Subsequent clinical trials showed that CSWT could reduce symptoms of myocardial ischemia and improve cardiac function in patients with severe coronary artery disease.
Study: NCT02765737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dehydrated Human Amnion/Chorion Membrane
Description: Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dehydrated Human Amnion/Chorion Membrane
Description: Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Study: NCT02173782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat ® high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat ® low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berodual® MDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00244049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling
Description: Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
Study: NCT00892021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSA-789

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03656341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Feet 4 Life
Description: 2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
Study: NCT04182919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phlai
Description: Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phlai
Description: Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
Study: NCT01976000

Intervention type: PROCEDURE
Intervention: multi-slice Computed Tomography angiography and three-dimensional reconstruction software